Clinical trial
Effects of Dapagliflozin on Progression of Alport Syndrome
NCT06226896 is registered in ClinicalTrials.gov with Nanjing University School of Medicine as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Effects of Dapagliflozin on Progression of Alport Syndrome
- Lead sponsor
- Nanjing University School of Medicine
- Phase
- Observational
- Overall status
- Active, not recruiting
- Start date
- November 15, 2023
- Completion date
- September 30, 2026
- Enrollment
- 222 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
alport syndrome